Results 191 to 200 of about 3,132 (216)
Some of the next articles are maybe not open access.

Association of Occlusive Retinal Vasculitis With Intravitreal Faricimab

JAMA Ophthalmology
This case report describes a patient with attenuation of retinal arterioles and veins associated with 2 blot hemorrhages and pallor of the inferotemporal retina without emboli.
Li, Ye, Chong, Robert, Fung, Adrian T.
openaire   +4 more sources

Faricimab-Associated Intraocular Inflammation with Features of Herpes Simplex Virus.

American journal of ophthalmology-glaucoma
OBJECTIVE Faricimab-associated intraocular inflammation (IOI) is an emerging concern. We aimed to investigate clinical features, management, and outcomes of severe IOI following faricimab therapy, with particular attention to cases displaying features ...
I. Janmohamed   +7 more
semanticscholar   +1 more source

Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies

Drug Design, Development and Therapy, 2023
Georgios D Panos   +2 more
exaly  

Aflibercept/faricimab

Reactions Weekly, 2023
openaire   +1 more source

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

Journal of Clinical Medicine, 2023
Hisanori Imai   +2 more
exaly  

Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases

Expert Opinion on Investigational Drugs, 2021
Carlo Traverso   +2 more
exaly  

From Bench to Bedside: Faricimab Enters the Clinic

Ophthalmic Surgery, Lasers and Imaging Retina, 2022
Cecilia Villanueva, Boone   +2 more
openaire   +2 more sources

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review

International Journal of Molecular Sciences, 2022
Jaroslaw Kociecki   +2 more
exaly  

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema

Medicina (Lithuania), 2023
Hisanori Imai   +2 more
exaly  

Home - About - Disclaimer - Privacy